Physician profile
Matthew D Mclaughlin
NPI 1215071469
$6,409.61
in general payments reported to CMS, 2019-2025
47 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $425 · 2021: $713 · 2022: $1,072 · 2023: $977 · 2024: $1,144 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.82 |
| Education | $363.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,352.24 | 2019-2025 | Xtandi, Padcev, Myrbetriq |
| Sumitomo Pharma America, INC. | $488.96 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $444.60 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $365.32 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $289.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $286.67 | 2019-2023 | |
| Abbvie INC. | $267.04 | 2019-2025 | |
| Urogen Pharma, INC. | $251.49 | 2020-2023 | Jelmyto |
| Coloplast Corp | $221.71 | 2021-2024 | Speedicath |
| Merck Sharp & Dohme LLC | $215.41 | 2022-2025 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $194.45 | 2020-2024 | Lynparza |
| Rochester Medical Corporation | $167.40 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $165.74 | 2020-2024 | Prolaris, Myrisk |
| Sun Pharmaceutical Industries INC. | $129.12 | 2019-2025 | Yonsa |
| Allergan, INC. | $117.69 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.